CoChat
Sign Up
Cited by 50

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells

Morell, Cecilia, Bort, Alicia, Vara-Ciruelos, Diana, Ramos-Torres, Ágata, Altamirano-Dimas, Manuel, Díaz-Laviada, Inés, Rodríguez-Henche, Nieves·2016·PLOS ONE
DOI 10.1371/journal.pone.0162977PMC PMC5023108
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0162977

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 58

  1. J Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, International journal of cancer Journal international du cancer, 136, E359, 10.1002/ijc.29210 · DOI · Paper page
  2. FG Rick, 2015, Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer, Urologic oncology, 33, 270, 10.1016/j.urolonc.2014.11.006 · DOI
  3. DJ Samson, 2002, Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma, Cancer, 95, 361, 10.1002/cncr.10647 · DOI
  4. AA Shafi, 2013, Androgen receptors in hormone-dependent and castration-resistant prostate cancer, Pharmacology & therapeutics, 140, 223, 10.1016/j.pharmthera.2013.07.003 · DOI
  5. F Saad, 2015, Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer, Urology, 86, 852, 10.1016/j.urology.2015.07.034 · DOI
  6. T Karantanos, 2013, Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches, Oncogene, 32, 5501, 10.1038/onc.2013.206 · DOI
  7. D Hirano, 2004, Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy, European urology, 45, 586, 10.1016/j.eururo.2003.11.032 · DOI
  8. H Beltran, 2014, Aggressive variants of castration-resistant prostate cancer. Clinical cancer research: an official journal of the, American Association for Cancer Research, 20, 2846
  9. AW Wyatt, 2015, Targeting the adaptive molecular landscape of castration-resistant prostate cancer, EMBO molecular medicine, 7, 878, 10.15252/emmm.201303701 · DOI
  10. O Cussenot, 1996, Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma, The Journal of urology, 155, 1340, 10.1016/S0022-5347(01)66261-X · DOI
  11. S Isshiki, 2002, Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer, The Journal of urology, 167, 512, 10.1016/S0022-5347(01)69075-X · DOI
  12. T Hvamstad, 2003, Neuroendocrine serum tumour markers in hormone-resistant prostate cancer, European urology, 44, 215, 10.1016/S0302-2838(03)00257-4 · DOI
  13. Y Sun, 2009, Neuroendocrine differentiation in prostate cancer, American journal of translational research, 1, 148
  14. PA Abrahamsson, 1999, Neuroendocrine cells in tumour growth of the prostate, Endocrine-related cancer, 6, 503, 10.1677/erc.0.0060503 · DOI
  15. S Terry, 2014, The many faces of neuroendocrine differentiation in prostate cancer progression, Frontiers in oncology, 4, 60, 10.3389/fonc.2014.00060 · DOI
  16. CG Sauer, 2006, Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma, The Prostate, 66, 227, 10.1002/pros.20338 · DOI
  17. YJ Bang, 1994, Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP, Proceedings of the National Academy of Sciences of the United States of America, 91, 5330, 10.1073/pnas.91.12.5330 · DOI
  18. ME Cox, 1999, Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression, Cancer research, 59, 3821
  19. PD Deeble, 2001, Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells, Molecular and cellular biology, 21, 8471, 10.1128/MCB.21.24.8471-8482.2001 · DOI
  20. I Gutierrez-Canas, 2005, Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K, The Prostate, 63, 44, 10.1002/pros.20173 · DOI
  21. R Shen, 1997, Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium, Urologic oncology, 3, 67, 10.1016/S1078-1439(97)00039-2 · DOI
  22. P Saftig, 2009, Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function, Nature reviews Molecular cell biology, 10, 623, 10.1038/nrm2745 · DOI · Paper page
  23. M Fukuda, 1991, Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking, The Journal of biological chemistry, 266, 21327, 10.1016/S0021-9258(18)54636-6 · DOI
  24. EL Eskelinen, 2006, Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy, Molecular aspects of medicine, 27, 495, 10.1016/j.mam.2006.08.005 · DOI
  25. Y Tanaka, 2000, Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice, Nature, 406, 902, 10.1038/35022595 · DOI · Paper page
  26. I Nishino, 2000, Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease), Nature, 406, 906, 10.1038/35022604 · DOI · Paper page
  27. Y Endo, 2015, Danon disease: a phenotypic expression of LAMP-2 deficiency, Acta neuropathologica, 129, 391, 10.1007/s00401-015-1385-4 · DOI
  28. EL Eskelinen, 2005, Unifying nomenclature for the isoforms of the lysosomal membrane protein LAMP-2, Traffic, 6, 1058, 10.1111/j.1600-0854.2005.00337.x · DOI
  29. AM Cuervo, 2014, Chaperone-mediated autophagy: roles in disease and aging, Cell research, 24, 92, 10.1038/cr.2013.153 · DOI
  30. Y Fujiwara, 2013, Discovery of a novel type of autophagy targeting RNA, Autophagy, 9, 403, 10.4161/auto.23002 · DOI
  31. Y Fujiwara, 2013, Direct uptake and degradation of DNA by lysosomes, Autophagy, 9, 1167, 10.4161/auto.24880 · DOI
  32. F Janku, 2011, Autophagy as a target for anticancer therapy, Nature reviews Clinical oncology, 8, 528, 10.1038/nrclinonc.2011.71 · DOI
  33. L Galluzzi, 2015, Autophagy in malignant transformation and cancer progression, The EMBO journal, 34, 856, 10.15252/embj.201490784 · DOI · Paper page
  34. JM Farrow, 2014, Autophagy as a modulator and target in prostate cancer, Nature reviews Urology, 11, 508, 10.1038/nrurol.2014.196 · DOI
  35. ME Wright, 2003, Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells, Molecular endocrinology, 17, 1726, 10.1210/me.2003-0031 · DOI · Paper page
  36. AM Cuervo, 1996, A receptor for the selective uptake and degradation of proteins by lysosomes, Science, 273, 501, 10.1126/science.273.5274.501 · DOI · Paper page
  37. JP Luzio, 2007, Lysosomes: fusion and function, Nature reviews Molecular cell biology, 8, 622, 10.1038/nrm2217 · DOI
  38. K Kannan, 1996, Lysosome-associated membrane proteins h-LAMP1 (CD107a) and h-LAMP2 (CD107b) are activation-dependent cell surface glycoproteins in human peripheral blood mononuclear cells which mediate cell adhesion to vascular endothelium, Cellular immunology, 171, 10, 10.1006/cimm.1996.0167 · DOI
  39. M Damaghi, 2015, Chronic acidosis in the tumour microenvironment selects for overexpression of LAMP2 in the plasma membrane, Nature communications, 6, 8752, 10.1038/ncomms9752 · DOI
  40. RA Gottlieb, 2015, Untangling autophagy measurements: all fluxed up, Circulation research, 116, 504, 10.1161/CIRCRESAHA.116.303787 · DOI
  41. H Murillo, 2001, Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state, Endocrinology, 142, 4795, 10.1210/endo.142.11.8467 · DOI
  42. S Xie, 2004, Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells, The Prostate, 60, 61, 10.1002/pros.20048 · DOI
  43. C Morell, 2016, The cannabinoid WIN 55,212–2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells, Prostate Cancer Prostatic Dis
  44. H Appelqvist, 2013, The lysosome: from waste bag to potential therapeutic target, Journal of molecular cell biology, 5, 214, 10.1093/jmcb/mjt022 · DOI · Paper page
  45. N Fehrenbacher, 2008, Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2, Cancer research, 68, 6623, 10.1158/0008-5472.CAN-08-0463 · DOI
  46. K Furuta, 2001, Expression of lysosome-associated membrane proteins in human colorectal neoplasms and inflammatory diseases, The American journal of pathology, 159, 449, 10.1016/S0002-9440(10)61716-6 · DOI
  47. T Saha, 2012, LAMP2A overexpression in breast tumors promotes cancer cell survival via chaperone-mediated autophagy, Autophagy, 8, 1643, 10.4161/auto.21654 · DOI
  48. M Kon, 2011, Chaperone-mediated autophagy is required for tumor growth, Science translational medicine, 3, 109ra17
  49. A Ibrahim-Hashim, 2012, Systemic buffers inhibit carcinogenesis in TRAMP mice, The Journal of urology, 188, 624, 10.1016/j.juro.2012.03.113 · DOI
  50. EA Dunlop, 2014, mTOR and autophagy: a dynamic relationship governed by nutrients and energy, Semin Cell Dev Biol, 36, 121, 10.1016/j.semcdb.2014.08.006 · DOI
  51. M Matsuda-Lennikov, 2014, Lysosomal interaction of Akt with Phafin2: a critical step in the induction of autophagy, PloS one, 9, e79795, 10.1371/journal.pone.0079795 · DOI
  52. M Noguchi, 2014, The links between AKT and two intracellular proteolytic cascades: ubiquitination and autophagy, Biochim Biophys Acta, 1846, 342
  53. QW Fan, 2010, Akt and autophagy cooperate to promote survival of drug-resistant glioma, Sci Signal, 3, ra81
  54. PC Chang, 2014, Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells, PloS one, 9, e88556, 10.1371/journal.pone.0088556 · DOI
  55. Y Zhu, 2014, Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST), The Prostate, 74, 1086, 10.1002/pros.22819 · DOI
  56. AV Lapuk, 2012, From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer, The Journal of pathology, 227, 286, 10.1002/path.4047 · DOI
  57. R Manjithaya, 2011, Autophagy: a broad role in unconventional protein secretion?, Trends Cell Biol, 21, 67, 10.1016/j.tcb.2010.09.009 · DOI
  58. M Ponpuak, 2015, Secretory autophagy, Curr Opin Cell Biol, 35, 106, 10.1016/j.ceb.2015.04.016 · DOI

Cited by

Sorted by citations

See all 50

Metadata

Authors
Morell, C., Bort, A., Vara-Ciruelos, D., Ramos-Torres, Á., Altamirano-Dimas, M., Díaz-Laviada, I., & Rodríguez-Henche, N.
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2016-09-14
Volume
11
Issue
9
Pages
e0162977
ISSN
1932-6203
DOI
10.1371/journal.pone.0162977
PMC
PMC5023108
Cited by
50
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • Spanish Ministry of Economy and Competitiveness (BFU2012-31444)
  • Junta de Comunidades de Castilla-LaMancha and European Commission FEDER Funds (POII11-0159-0054)
  • Comunidad de Madrid (S2010-BMD2308)
  • Fundación Tatiana Pérez de Guzmán el Bueno (2013-001)
  • Universidad de Alcalá (PI2005/063)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review